Porcine rotavirus VP7 polyepitope fusion protein, and preparation method and application thereof

By constructing a multi-epitope fusion protein of porcine rotavirus VP7 and Salmonella typhimurium flagellate protein FliCS.T, we have solved the problems of poor prevention and control efficacy of existing vaccines and the paradox of immunogenicity and safety, as well as the conflict between structural stability and functional activity in the application of flagellate proteins, and achieved a highly efficient immune protection effect.

CN120682325BActive Publication Date: 2026-06-23YANGZHOU UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
YANGZHOU UNIV
Filing Date
2025-07-10
Publication Date
2026-06-23

AI Technical Summary

Technical Problem

Existing porcine rotavirus vaccines are ineffective due to serotype diversity, viral mutation, frequent interspecies transmission and gene rearrangement. Furthermore, bacterial flagellin, as an immune adjuvant, faces paradoxes regarding immunogenicity and safety, as well as conflicts between structural stability and functional activity.

Method used

By fusing the dominant B-cell neutralizing epitope of porcine rotavirus VP7 protein with the flagellated protein FliCS.T from Salmonella typhimurium, a multi-epitope fusion protein was constructed. Using FliCS.T as the backbone protein, the VP7 protein neutralizing epitope was embedded into the hypervariable region of FliCS.T through the multi-epitope fusion antigen technology (MEFA) platform, thereby achieving functional fusion expression of VP7 and FliCS.T.

Benefits of technology

It significantly enhances the immune protection against porcine rotavirus, induces high levels of neutralizing antibodies and cellular immune responses, reduces production costs, simplifies immunization procedures, and provides a broad-spectrum and highly effective vaccine prevention and control program.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120682325B_ABST
    Figure CN120682325B_ABST
Patent Text Reader

Abstract

The application discloses a porcine rotavirus VP7 protein conserved dominant B cell antigen epitope peptide or a combination thereof or a nucleic acid molecule and application, and further discloses a porcine rotavirus VP7 protein polyepitope fusion protein and a preparation method and application thereof.The polyepitope fusion protein can not only induce high-level specific antibody response and cellular immune response to the VP7 protein, effectively inhibit porcine rotavirus infection, but also has high safety and stability.Compared with a traditional fusion protein, the polyepitope fusion protein has significant advantages in production cost and immunization efficacy, and provides a feasible porcine rotavirus prevention and control scheme for the pig industry.
Need to check novelty before this filing date? Find Prior Art